Azenta, Inc. 8-K

What Happened

• On July 1, 2026 Azenta, Inc. (through Azenta Germany GmbH) closed the transaction to acquire B Medical Systems S.à r.l. and entered into a $35 million vendor loan to Thelema S.à r.l. to support completion of the deal. The company disclosed the arrangements in an 8-K and issued a press release on July 8, 2026 announcing the transaction closing.
• The loan bears interest at 6.0% per annum, matures three months after funding, is payable in full at maturity, and may be prepaid without penalty. The loan is secured by a first-priority pledge of 100% of B Medical’s equity, and the purchase agreement was amended so $35 million of the purchase price is satisfied via this vendor loan.

Key Details

• Vendor loan principal: $35,000,000; interest rate: 6.0% per year; maturity: 3 months from funding.
• Security: first-priority pledge over 100% of B Medical Systems S.à r.l. equity under a Share Pledge Agreement.
• Related party: Thelema S.à r.l. is majority-owned by Luc Provost (Azenta Vice President and CEO of B Medical). Mr. Provost did not participate in negotiation/approval; the Audit Committee approved the arrangements.
• The loan agreement restricts Thelema’s ability to take on more debt or dispose of assets but allows for acquisition financing; Azenta Germany may cooperate with future acquisition/refinancing, which could subordinate or release Azenta’s pledge.

Why It Matters

• For investors, this reduces Azenta’s immediate cash outlay for the acquisition by converting $35M of the purchase price into a short-term vendor loan while leaving B Medical presented as a discontinued operation in prior financials.
• The related-party nature and short-term, secured loan structure are material governance and credit considerations: the pledge secures repayment but may be subordinated if Thelema obtains later acquisition or refinancing debt. The Audit Committee reviewed and approved the transaction per company policy.